Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
06/2003
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114418 Analgesics; antiinflammatory and arthritic agents; osteoarthritis; rheumatic diseases; gastrointestinal, nervous system, respiratory disorders; wound healing agents; vision defects; kits
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113269 Medical combinations comprising tiotropium and fluticasone proprionate
06/19/2003CA2655959A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469306A1 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2464341A1 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
06/18/2003EP1319404A2 Composition for treating and/or prophylaxis of tumors of the breast
06/18/2003EP1319015A2 Olfactory and pheromones g-protein coupled receptors
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1318997A1 Pyrazole compounds useful as protein kinase inhibitors
06/18/2003EP1318837A2 Method of treating estrogen receptor positive carcinoma
06/18/2003EP1318836A2 Treatment of hyperproliferative diseases
06/18/2003EP1318814A2 Triazole compounds useful as protein kinase inhibitors
06/18/2003EP1232247A4 Modulation of signal transduction
06/18/2003EP1098874B1 Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
06/18/2003EP0907631B1 Inorganic ion receptor-active compounds
06/18/2003CN1424915A Oral, nasal and pulmonary dosage formulations of copolymer1
06/17/2003US6579989 Sulphostin analogue and process for producing sulphostin and its analogue
06/17/2003US6579967 Cyclic peptide of given amino acid sequence; improves binding strength by adding a carbamoyl moiety at N-terminus; useful in determining tissue/cellular expression and in drug screening
06/17/2003US6579700 Neuropeptide Y (NPY); isolated peptide of given amino acid sequence; may be useful in regulating central and peripheral nervous and endocrine systems
06/12/2003WO2003048772A2 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin
06/12/2003WO2003048206A2 Growth hormone agonist peptides and their uses
06/12/2003WO2003048181A1 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048141A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
06/12/2003WO2003048109A1 Novel glucagon antagonists
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047573A1 Insulin resistance improving agents
06/12/2003WO2003047555A1 Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
06/12/2003WO2003047548A1 Pharmaceutical compositions in the form of gel or solution based on dihydrotestosterone, preparation method and uses thereof
06/12/2003WO2003047504A2 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109507 Relates to semisolid transcutaneous medicaments based on at least one oxidation-sensitive progestin or a pharmaceutically acceptable derivative thereof. The medicaments comprise ascorbic acid, an ascorbic acid derivative or a salt thereof
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003CA2537913A1 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468827A1 Insulin resistance improving agents
06/12/2003CA2465395A1 Transdermal therapeutic systems containing steroid hormones and containing propylene glycol monocaprylate
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317921A1 Gel or solution containing dihydrotestosterone, its manufacture and use
06/11/2003EP1317470A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
06/11/2003EP1317456A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317286A2 Contraception process and administration form for the same
06/11/2003EP1317270A1 Exemestane for the treatment of oestrogen-dependent cancers
06/11/2003EP1248637A4 Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity
06/11/2003EP1131065B1 Dialkylfumarates for the treatment of autoimmune diseases
06/11/2003EP0892787B1 Novel alpha-hydroxylic acid derivatives, their production and use
06/11/2003CN1423700A Multifunctional polypeptides comprising a binding site to and epitope of the NKG2D receptor complex
06/11/2003CN1423646A Hetero cyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
06/11/2003CN1423645A 维他命d类似物 Vitamin d analogues
06/11/2003CN1423633A Azetidine derivatives, preparation thereof and pharmaceutical compositions
06/11/2003CN1423627A 维生素d类似物 Vitamin d analogues
06/11/2003CN1423560A Male contraceptive formulation comprising norethisterone
06/11/2003CN1423557A Intracorporeal medicaments for photodynamic treatment of disease
06/11/2003CN1111070C Medicinal composition for treating thyroidism
06/11/2003CN1111036C Medicine for treating benign goiter
06/10/2003US6576656 Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser
06/10/2003US6576648 Compound with growth hormone releasing properties
06/10/2003US6576645 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
06/10/2003US6576252 Composition providing calming, stress hormone regulating and immune stimulation effect, which comprises component including combination of linoleic and linolenic acids in specified ratio, and component taken from flavonoid group
06/10/2003CA2192354C Corticotropin releasing factor against antagonist
06/06/2003CA2413479A1 Kit for reducing aching
06/05/2003WO2003046574A2 Complement c3 precursor biopolymer markers indicative of insulin resistance
06/05/2003WO2003046556A2 Globin biopolymer markers indicative of insulin resistance
06/05/2003WO2003046141A2 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
06/05/2003WO2003046135A2 Osteopontin-related compositions and methods
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045974A2 Methods and compositions for derepression of iap-inhibited caspase
06/05/2003WO2003045972A1 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
06/05/2003WO2003045955A1 Use of selective potassium channel openers
06/05/2003WO2003045954A1 Use of selective potassium channel openers
06/05/2003WO2003045946A1 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
06/05/2003WO2003045926A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003WO2003045918A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders
06/05/2003WO2003045424A1 Methods of compositions for normalizing lipid levels in mammalian tissues
06/05/2003WO2003045419A1 Injection solution comprising an lhrh antagonist
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2003035043A3 Pharmaceutical formulation comprising more than 15% tamoxifen
06/05/2003WO2002031514A3 A method of determining the initial dose of vitamin d compounds
1 ... 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 ... 290